Latest filing published 29 Sept 2026 for IGC Pharma, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Ram Mukunda, listed as chief executive, appears in our data through filings on IGC Pharma, Inc. shares, published by SEC (Form 4). The record holds 14 filings, for trades running from 13 May 2021 to 25 September 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 29 September 2026: a transaction, in IGC Pharma, Inc. Typically, a trade is published a median of 5 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations